Top

Published in:

01-05-2018 | Neurology and Preclinical Neurological Studies - Original Article

Interleukin 6 and complement serum level study in Parkinson’s disease

Authors: Branislav Veselý, Michal Dufek, Vojtech Thon, Miroslav Brozman, Silvia Királová, Tatiana Halászová, Eva Koriťáková, Ivan Rektor

Published in: Journal of Neural Transmission | Issue 5/2018

Abstract

The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson’s disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.

Auriacombe S, Grossman M, Carvell S, Gollomp S (1993) Verbal fluency deficits in Parkinson’s disease. Neuropsychology 7:182–192CrossRef

Benton AL (1983) Contributions to neuropsychological assessment. Oxford University Press, New York

Berczi I, Quintanar-Stephano A, Kovacs K (2009) Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann N Y Acad Sci 1153:220–239CrossRefPubMed

Bonifati DM, Kishore U (2007) Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44:999–1010CrossRefPubMed

Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, Stepien A (2008) Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF-alpha, and IFNgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 441:158–162CrossRefPubMed

Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56CrossRefPubMedPubMedCentral

Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW (1999) Association of circulating TNF-alpha and IL-6 with aging and parkinsonism. Acta Neurol Scand 100:34–41CrossRefPubMed

Dufek M, Hamanová M, Lokaj L, Goldemund D, Rektorová I, Michálková Z, Sheardová K, Rektor I (2009) Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism Relat Disord 15:318–320CrossRefPubMed

Dufek M, Rektorová I, Thon V, Lokaj L, Rektor I (2015) Interleukin-6 may contribute to mortality in Parkinson’s disease patients: a 4 year prospective study. Parkinson’s Dis 2015:898192

Dunn AJ (2006) Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 6:52–68CrossRefPubMedPubMedCentral

Fahn S, Elston RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan, New York, pp 153–163

Finehout EJ, Franck Z, Lee KH (2005) Complement proteins isoforms in CSF as possible biomarkers for neurodegenerative diseases. Dis Markers 11:93–101CrossRef

Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed

Freedman M, Kaplan E, Delis D, Morris R (1994) Clock drawing: a neuropsychological analysis. Oxford University Press, New York

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMed

Hoffmann KW, Schuh Schumacher AF, SauteJ Townsend R, Fricke D, Leke R, Souza DO, Valmor Portela L, Fagundes Chaves ML, Rieder CRM (2009) Interleukin-6 serum levels in patients with Parkinson’s disease. Neurochem Res 34:1401–1404CrossRef

Honglei C, Shumin M, Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1064CrossRef

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMedPubMedCentral

Kang Sujin, Tanaka Toshio, Kishimoto Tadamitsu (2015) Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol 27(1):21–29CrossRefPubMed

Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186CrossRefPubMed

Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O (2012) Nonmotor symptoms in patients with Parkinson’s disease—correlations with inflammatory cytokines in serum. PLoS One 7:e47387CrossRefPubMedPubMedCentral

Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O (2013) Cerebrospinal fluid inflammatory markers in Parkinson’s disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 33:183–189CrossRefPubMed

Mahoney FI, Barthel DW (1965) Functional evaluation: the BARTHEL index. MD State Med J 14:61–65PubMed

Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994) Interleukin-1beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150CrossRefPubMed

Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming factor levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 211:13–16CrossRefPubMed

Montgomery SA, Asberg MA (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389CrossRefPubMed

Müller T, Blum-Degen D, Przuntek H, Kuhn W (1998) Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol Scand 98:142–144CrossRefPubMed

Olson KE, Gendelman HE (2016) Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson’s disease. Curr Opin Pharmacol 26:87–95CrossRefPubMed

Pålhagen S, Qi H, Mårtensson B, Wålinder J, Granérus AK, Svenningsson P (2010) Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression. J Neurol 257:524–532CrossRefPubMed

Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson’s disease: a systematic review and meta-analysis. JAMA Neurol 73:1316–1324CrossRefPubMed

Reyes MA, Perez-Lloret SP, Roldan Gerscovich EG, Martin ME, Leiguarda R, Merello M (2009) Addenbrooke’s Cognitive Examination validation in Parkinson’s disease. Eur J Neurol 16:142–147CrossRefPubMed

Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K, Barone P (2015) Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord 21:1219–1226CrossRefPubMed

Scalzo P, Kümmer A, Cardoso F, Teixeira AL (2010) Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci Lett 468:56–58CrossRefPubMed

Schwab C, Steele JC, McGeer PL (1996) Neurofibrillary tangles of Guam Parkinson-dementia are associated with reactive microglia and complement proteins. Brain Res 707:196–205CrossRefPubMed

Umemura A, Oeda T, Yamamoto K (2015) Baseline plasma C-reactive protein concentrations and motor prognosis in Parkinson disease. PLoS One 10(8):0136722

Wechsler D (1997) Wechsler memory scale the third edition, WMS-III. The Psychological Corporation, San Antonio

Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, ICICLE-PD Study Group et al (2016) Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Mov Disord 31(7):995–1003CrossRefPubMedPubMedCentral

Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson’s disease recognized by antibodies to complement proteins. Acta Neuropathol 84:100–104CrossRefPubMed

Title: Interleukin 6 and complement serum level study in Parkinson’s disease
Authors: Branislav Veselý
Michal Dufek
Vojtech Thon
Miroslav Brozman
Silvia Királová
Tatiana Halászová
Eva Koriťáková
Ivan Rektor
Publication date: 01-05-2018
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 5/2018
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-018-1857-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Interleukin 6 and complement serum level study in Parkinson’s disease

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Neuroinflammatory responses in Alzheimer’s disease

Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer’s disease

Kynurenine is correlated with IL-1β in plasma of schizophrenia patients

Let’s make microglia great again in neurodegenerative disorders

Differential contribution of microglia and monocytes in neurodegenerative diseases

In vivo PET imaging of neuroinflammation in Alzheimer’s disease